Forecast Of The Day: Boston Scientific’s Cardiac Rhythm Management Revenue
What?
Boston Scientific (NYSE:BSX) Revenue from Cardiac Rhythm Management rose from around $1.94 billion in 2019 to $2 billion in 2021. Trefis expects the metric to grow to about $2.15 billion by 2024.
Why?
Relevant Articles
- What Trends Will Drive Boston Scientific’s Q3?
- What’s Behind The 2x Rise In Boston Scientific Stock?
- Watchman In Focus As Boston Scientific Reports Its Q2
- What Drove A Nearly 2x Rise In Boston Scientific’s Profits?
- Should You Pick Boston Scientific Stock After A Solid Q4 And 13% Uptick This Year?
- What’s Next For Boston Scientific Stock After 5% Gains In A Week?
We expect growth to be driven by new products, as well as higher instances of cardiac disease.
So What?
We remain positive on BSX stock with a $49 price estimate, which is about 5% ahead of the current market price.
What if you’re looking for a more balanced portfolio instead? Our high-quality portfolio and multi-strategy portfolio have beaten the market consistently since the end of 2016.
| Returns | Dec 2022 MTD [1] |
2022 YTD [1] |
2017-22 Total [2] |
| BSX Return | 2% | 9% | 114% |
| S&P 500 Return | -6% | -20% | 71% |
| Trefis Multi-Strategy Portfolio | -7% | -23% | 210% |
[1] Month-to-date and year-to-date as of 12/28/2022
[2] Cumulative total returns since the end of 2016
Invest with Trefis Market Beating Portfolios
See all Trefis Price Estimates
See all Trefis Price Estimates